Zobrazeno 1 - 10
of 4 556
pro vyhledávání: '"C, Ou"'
Autor:
Ethan Bustad, Emma Mudrock, Elizabeth M. Nilles, Andrea Mcquate, Monica Bergado, Alden Gu, Louie Galitan, Natalie Gleason, Henry C. Ou, David W. Raible, Rafael E. Hernandez, Shuyi Ma
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Ototoxicity is a debilitating side effect of over 150 medications with diverse mechanisms of action, many of which could be taken concurrently to treat multiple conditions. Approaches for preclinical evaluation of drug-drug interactions
Externí odkaz:
https://doaj.org/article/5b337905b38c463383e4f19a5a9a8ec3
Autor:
Constantine Tam, Mazyar Shadman, Jeff Sharman, Gavin Cull, Tycel Phillips, Judith Trotman, Aileen Cohen, Heather Allewelt, Rocco Crescenzo, Richard Delarue, Heather Zhang, Bilal Tariq, Sri Sahasranaman, Ying C Ou, Ian W Flinn
Publikováno v:
HemaSphere, Vol 7, p e70124b5 (2023)
Externí odkaz:
https://doaj.org/article/8d11dcd7c056425c884e00b51e99bc6f
Autor:
Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman, Ying C. Ou
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 441-454 (2021)
Abstract A physiologically based pharmacokinetic (PBPK) model was developed to evaluate and predict (1) the effect of concomitant cytochrome P450 3A (CYP3A) inhibitors or inducers on the exposures of zanubrutinib, (2) the effect of zanubrutinib on th
Externí odkaz:
https://doaj.org/article/c6ef1cbd2e704a50ba2bf248d270e404
Autor:
Ying C. Ou, Lucy Liu, Bilal Tariq, Kun Wang, Ashutosh Jindal, Zhiyu Tang, Yuying Gao, Srikumar Sahasranaman
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 764-772 (2021)
Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/r
Externí odkaz:
https://doaj.org/article/879d1e514a2645fb9a2b15ee786ead7c
Autor:
Song Mu, Borje Darpo, Zhiyu Tang, William Novotny, Manal Tawashi, Hongqi Xue, Michael Willett, Leo Lin, Sri Sahasranaman, Ying C. Ou
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 5, Pp 923-931 (2020)
This thorough QT (TQT) study evaluated the effect of zanubrutinib on electrocardiogram (ECG) parameters by using concentration‐QTc (C‐QTc) analysis as the primary analysis for this study. Part A of the study determined the safety and tolerability
Externí odkaz:
https://doaj.org/article/e0ea160c88114e70927aa41ba7867992
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 6, Pp n/a-n/a (2021)
Abstract Zanubrutinib is a highly selective, potent, orally available, targeted covalent inhibitor (TCI) of Bruton's tyrosine kinase (BTK). This work investigated the in vitro drug metabolism and transport of zanubrutinib, and its potential for clini
Externí odkaz:
https://doaj.org/article/5b5ab68ce63d4effa6ef18a32a9a79e9
Publikováno v:
Current Osteoporosis Reports. 21:56-64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e0098e71c53fd189f9689cf97ee0709
https://doi.org/10.1007/s11914-022-00769-0
https://doi.org/10.1007/s11914-022-00769-0
Publikováno v:
European Urology Open Science, Vol 19, Iss , Pp e2366- (2020)
Externí odkaz:
https://doaj.org/article/dce7195bcd654ce1a450a0e53bc82887
Autor:
Charles C. Wykoff, Muneeswar G. Nittala, Cecilia Villanueva Boone, Hannah J. Yu, Wenying Fan, Swetha Bindu Velaga, Justis P. Ehlers, Michael S. Ip, SriniVas R. Sadda, Brenda Zhou, Alexander M. Rusakevich, Shaun I.R. Lampen, Sunil K. Srivastava, Jamie L. Reese, Amy Babiuch, Katherine Talcott, Natalia Figueiredo, Sari Yordi, Jenna Hach, William C. Ou, Richard H. Fish, Matthew S. Benz, Eric Chen, Rosa Y. Kim, James C. Major, Ronan E. O’Malley, David M. Brown, Ankoor R. Shah, Amy C. Schefler, Tien P. Wong, Christopher R. Henry, Sagar B. Patel, Vy T. Nguyen, Kelly L. Larkin
Publikováno v:
Ophthalmology Retina. 6:557-566
Retinal nonperfusion (RNP) is an important biomarker for diabetic retinopathy (DR). Data suggest that consistent anti-VEGF pharmacotherapy can slow RNP development. The RECOVERY trial evaluated the impact of aflibercept (Eylea, Regeneron) on RNP amon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::520fbafe11bbd0b0dce6622428dd94c0
https://doi.org/10.1016/j.oret.2022.02.013
https://doi.org/10.1016/j.oret.2022.02.013
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.